antivirals

News

Aicuris acquisition delivers new drug for Asahi Kasei

Asahi Kasei's $920m takeover of Germany's Aicuris in April has paid off with FDA approval for the herpes simplex virus drug at the heart of the deal.

News

England close to eliminating hep C thanks to treatment drive

England is on track to be one of the first countries in the world to eliminate hepatitis C, thanks to a national diagnosis and treatment programme.

News

Island Pharma drug cleared for Bundibugyo Ebola use

Island Pharma has been granted the approvals needed to allow compassionate use of its antiviral galidesivir in the Bundibugyo Ebola outbreak.

News

As Ebola deaths climb, search begins for vaccine

The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola and fast-track clinical trials.

News

Asahi Kasei buys antiviral firm Aicuris for €780m

Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.

News

Hyundai Bio plans trials of antiviral for dengue fever

South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral

Aicuris acquisition delivers new drug for Asahi Kasei

England close to eliminating hep C thanks to treatment drive

Island Pharma drug cleared for Bundibugyo Ebola use

As Ebola deaths climb, search begins for vaccine

Asahi Kasei buys antiviral firm Aicuris for €780m

Hyundai Bio plans trials of antiviral for dengue fever

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

antivirals

Editor's Picks